Desmoid Tumor clinical trials at UCSF

3 in progress, 2 open to eligible people

Desmoid tumors are rare, non-cancerous growths found in connective tissues. UCSF is researching the effects of a drug called tegavivint on these tumors and other solid tumors. UCSF is also collecting health data from young patients to track cancer developments over time.

Showing trials for

  • Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    open to eligible people ages 12 months to 30 years

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with…

    San Francisco, California and other locations

  • Project: Every Child for Younger Patients With Cancer

    open to eligible people ages up to 25 years

    This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.

    Oakland, California and other locations

  • New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

    Sorry, in progress, not accepting new patients

    This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that has grown after at least one form of treatment by mouth or in the vein that cannot be removed by…

    Oakland, California and other locations

Our lead scientists for Desmoid Tumor research studies include .

Last updated: